Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study

Clicks: 329
ID: 117304
2017
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome comprising familial/genetic HLH (FHL) and secondary HLH. In the HLH-94 study, with an estimated 5-year probability of survival (pSu) of 54% (95% confidence interval, 48%-60%), systemic therapy included etoposid …
Reference Key
e2017bloodconfirmed Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bergsten E;Horne A;Aricó M;Astigarraga I;Egeler RM;Filipovich AH;Ishii E;Janka G;Ladisch S;Lehmberg K;McClain KL;Minkov M;Montgomery S;Nanduri V;Rosso D;Henter JI;;
Journal Blood
Year 2017
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/28935695
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't female male Infant lymphohistiocytosis longitudinal studies hemophagocytic / mortality* hematopoietic stem cell transplantation / mortality cyclosporine / therapeutic use etoposide / therapeutic use* dexamethasone / therapeutic use* hemophagocytic / drug therapy* jan-inge henter annacarin horne pmid:28935695 pmc5785801 doi:10.1182/blood-2017-06-788349 elisabet bergsten antineoplastic combined chemotherapy protocols / therapeutic use hematopoietic stem cell transplantation / methods

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.